Science News & Views
I comment on the news I receive from various sources
Sunday, May 8, 2016
Thursday, April 7, 2016
Tuesday, April 5, 2016
Watch what you eat; there may be bristles in your burger
At times, one gets a feeling that physicians and specialists do not get proper subjects for detailed research. But we must not be extremely critical on such matters as mundane research which just collates and lists observations is very useful; it may contain life-saving messages
Research that examines the incidence of injuries caused by ingesting wire bristles from grill brushes, and prompts physicians and consumers to take notice before the summer grilling season, published in the April 2016 issue of Otolaryngology-Head and Neck Surgery is one such example.
What are the notable findings?
- Wire-bristle grill brushes, used for cleaning grill grates, may lose bristles when used. These bristles can adhere to the grill, become stuck to food, and then accidentally be ingested. A literature and national database review yielded case reports and documented injuries from ingestion, sometimes requiring surgery.
- The public and physicians may not be cognizant of the dangers and the medical implications of wire bristle injuries. Lack of awareness can result in a delayed diagnosis and intervention.
- Data show that the majority of these injuries tend to be located in the head and neck region, with incidents more commonly occurring in the summer months.
- Use of alternative cleaning methods may reduce this problem.
Researchers reviewed the literature and used the Consumer Product Safety Commission's National Electronic Injury Surveillance System and the consumer reported injury database SaferProducts.gov to estimate emergency department visits for wire bristle injuries. They counted 1698 cases presented to emergency departments between 2002 and 2014 but caution that the estimate doesn't include cases presenting at urgent care facilities or other outpatient settings.
"The issue is likely under-reported and thus underappreciated," said the study's lead author, C.W. David Chang, MD. "Because of the uncommon nature of wire bristle injuries, people may not be as mindful of the dangers and implications. Awareness among emergency department physicians, radiologists, and otolaryngologists is particularly important so that appropriate tests and examinations can be conducted."
The most common location of injury was the oral cavity and the oropharynx which includes the throat and tonsils. In all databases, injuries involving the esophagus and head and neck were more frequent than abdominal injuries.
Take home messages:
Consumers must exercise caution when cleaning grills with wire-bristle brushes; they must examine brushes prior to each use; they must not hesitate to discard them if bristles are loose. They must inspect cooking grates prior to cooking, and check into alternative cleaning methods.
Monday, April 4, 2016
Evacetrapib reduces LDL and increases HDL but doesn't reduce cardiovascular events
This news item is based on a presentation being made at the American College of Cardiology's 65th Annual Scientific Session
Cleveland Clinic researchers studying evacetrapib showed that despite reducing levels of low-density lipoprotein (LDL, or "bad" cholesterol) by 37 percent and raising levels of high-density lipoprotein (HDL, or "good" cholesterol) by 130 percent, the drug failed to reduce rates of major cardiovascular events, including heart attack, stroke, angina or cardiovascular death.
The ACCELERATE trial involved more than 12,000 patients at more than 540 sites who were at high risk for serious cardiovascular problems. They were randomized to receive either 130 milligrams of evacetrapib or a placebo daily, along with standard medical therapy throughout the trial. Study participants either had an acute coronary syndrome 30 days to one year before enrolling, had cerebrovascular atherosclerotic disease, had peripheral vascular disease, or had both diabetes and coronary artery disease.
Those receiving evacetrapib saw their LDL cholesterol levels reduced by 37 percent and their HDL levels increased by 130 percent. Still, the improvements in cholesterol did not result in any reduction in the occurrence of cardiovascular death, heart attack, stroke, coronary artery bypass surgery or hospitalization for chest pain due to unstable angina. Researchers observed a borderline significant reduction in all-cause mortality in the evacetrapib group; however, that was not driven by a decrease in cardiovascular death.
Researchers discontinued the phase 3, multi-center clinical trial in October 2015, on the recommendation of the independent Data Monitoring Committee after preliminary data suggested the study would not meet its primary endpoint of a reduction in major cardiovascular events.
"Here we have a paradox. The drug more than doubled HDL and lowered LDL levels by as much as many statins, but had no effect on cardiac events," said Steve Nissen, M.D., chairman of Cardiovascular Medicine at Cleveland Clinic. "These findings illustrate the importance of performing large, high-quality outcome trials. Just looking at the effects a therapy has on cholesterol levels doesn't always translate into clinical benefits."
"We were certainly hoping for different results, and are trying to understand why we didn't see a benefit from this drug" said Dr. A. Michael Lincoff, M.D., director of the Cleveland Clinic Coordinating Center for Clinical Research (C5Research) and a Principal Investigator on the study. "The trial raises questions about the benefits of raising HDL and the future of this class of drugs."
Despite widespread use of statins, many patients continue to experience cardiovascular events. Therefore, considerable efforts have been put into investigating whether the protective benefits of HDL cholesterol could be targeted as a form of therapy.
Evacetrapib is in a class of drugs known as cholesteryl ester transfer protein (CETP) inhibitors. They work by disrupting the process which normally transfers cholesterol from HDL cholesterol to LDL cholesterol in the body. Animal and genetic studies have suggested that CETP deficiency is cardioprotective; however, this is the third failure in this class of drugs. Results of a phase 3 clinical trial of the first drug, torcetrapib, showed an increase in adverse outcomes. Trials were stopped for dalcetrapib, a second CETP inhibitor, when it was also found to be ineffective. Evacetrapib was thought to be a promising approach because it is a potent CETP inhibitor and lacks the toxicity of torcetrapib.
Safety concerns were not raised by the trial, and the study didn't reveal any major side effects.
Sunday, April 3, 2016
Are there 'simple' methods to prevent heart attacks and stroke worldwide ?
Are there 'simple' methods to prevent heart attacks and stroke worldwide ? Researchers claim that there are three simple solutions to prevent heart attacks and stroke worldwide; they have been proven effective by an international team led by Hamilton medical researchers.
They are presenting the HOPE-3 trials at the 2016 American College of Cardiology (ACC) Scientific Session and Expo in Chicago this weekend.
Controversies on treatment of blood pressure with anti hypertensive drugs and statins to reduce cholesterol were attracting attention worldwide. The New England Journal of Medicine published three articles highlighting the results of recent trials in this important field.
The research team from the Population Health Research Institute (PHRI) of McMaster University and Hamilton Health Sciences studied more than 12,000 patients from 21 countries to evaluate drugs that can prevent cardiovascular diseases (CVD). These diseases lead to 18 million deaths and about 50 million heart attacks and strokes globally every year.
"These are incredibly important findings with potential for significant global impact," said Dr. Salim Yusuf, principal investigator and executive director of PHRI. "If just 10 percent of the world's population at intermediate risk of CVD is impacted, we're talking about 20 to 30 million people who could be helped by these drugs."
The three methods examined included two forms of therapy: Statins, a group of cholesterol-lowering drugs, and antihypertensives, a class of drugs used to treat high blood pressure. In addition, a combination of statins and antihypertensives was reviewed.
Under the name of HOPE-3, or Heart Outcomes Prevention Evaluation-3, the studies involved 228 centres looking at the effects of the three treatments in people at intermediate risk of, but without, clinical heart disease.
Statins proved to significantly and safely reduce CVD events by 25 per cent in patients at intermediate risk without CVD. Antihypertensives did not reduce major CVD events overall in the population studied, but did reduce such events in the group of people with hypertension, but not in those without hypertension. When combined, statins and antihypertensives reduced CVD events by 30 per cent--with a 40% benefit in those with hypertension, suggesting that patients with hypertension should not only lower their BP but also consider taking a statin.
The HOPE-3 research reports were led by Yusuf and Dr. Eva Lonn, both professors of medicine of McMaster's Michael G. DeGroote School of Medicine, and Jackie Bosch, an associate professor of the university's School of Rehabilitation Science.
"The HOPE-3 trial brings clarity in the management of blood pressure and cholesterol, two of the most common cardiovascular risk factors," said Lonn. "Primary prevention can be greatly simplified and made available to most intermediate-risk people worldwide."
Bosch added: "Treatment with a statin was remarkably safe and beneficial in our study, regardless of cholesterol or blood pressure levels, age, gender or ethnicity. We are incredibly encouraged by the study's results."
HOPE-3's findings will have a major influence on primary care in developed nations, where statins and antihypertensives are inexpensive, Yusuf added. While still relatively inexpensive in developing nations, the drugs are less affordable in relation to income. Still, Yusuf said the study's results hold promise everywhere as the price of these drugs start to come down.
"These simple methods can be used practically everywhere in the world, and the drugs will become even cheaper as more and more systems and people adopt these therapies," he said.
Yusuf, Lonn and Bosch are presenting the HOPE-3 trials at the 2016 American College of Cardiology (ACC) Scientific Session and Expo in Chicago this weekend.
I have to add the following paragraph extracted from Japan Today dated April 4, 2016 to indicate the conflict of interests of the authors:
"The study used 10 milligrams daily of rosuvastatin, sold as a generic or under the brand name Crestor. The editorial authors said other statins would likely have similar results. Crestor’s maker, AstraZeneca, and the Canadian Institutes of Health Research paid for the study. Yusuf reported receiving grants from both; and several co-researchers reported grants and personal fees from the company and other drug-makers."
Saturday, January 26, 2013
Feed cows with flax seed to get more nutritious dairy products
Feed cows
with flax seed to get more nutritious
dairy products
When I was young, I
liked to drink plenty of milk. As a matter
of fact, I liked all dairy products. I have heard our grandmother saying that
the taste of milk depends on the food
cow eats regularly. I did not believe it.
She knew it from closely watching our cows. Since our cows
were not allowed to graze in the fields
most of what they consume was stored
cattle feeds such as oil cakes and agricultural and food wastes. Our
grandmother claimed that if we feed cows with the wastes from jackfruit, milk
tastes differently compared to straw or grass. Herbs gave a special flavor .
OSU researcher Gerd Bobe led a study that fed flaxseed to
dairy cows and examined the effects to milk, cheese and butter. (Photo by
Hannah O'Leary.)
These observations were simply not grandma tales. Not
anymore! Researchers at the Oregon State University has shown that dairy cows that are fed flaxseed
produce more nutritious milk.
Their milk contained more omega-3
fatty acids and less saturated fat, the study found.
Diets high in saturated fat can
increase cholesterol and cause heart disease, while those rich in omega-3 and
other polyunsaturated fatty acids may reduce the risk of heart disease, studies
have shown.
Traditional cattle feed mixtures of
corn, grains, alfalfa hay and grass silage result in dairy products with low
concentrations of omega-3 and other polyunsaturated fats, according to Gerd
Bobe, the lead scientist on the study, which has been published online in the Journal
of Dairy Science.
Researchers fed ten pregnant cows at
OSU's dairy different amounts of flaxseed – up to seven percent of their daily
diet. They attempted to pinpoint the amount of flaxseed that would maximize the
amount of omega-3 in milk and dairy products without negatively affecting their
production and texture.
One of the special requirements of food
industry is that the products must maintain consistency. Otherwise, consumers
will find it unacceptable. Researchers carried out detailed studies to get the
right mix of flax seeds in cattle feed
Collaborators in OSU's food science
and technology department assisted in turning milk into butter and fresh
cheese, which were then tested for texture and nutritional composition.
Researchers found that feeding cows up to six pounds of extruded
flaxseed improved the fat profile without negatively affecting the production
and texture of the milk and other dairy products. Extrusion presses raw ground
flaxseed into pellets with heat.
At six pounds per day, saturated
fatty acids in whole milk fat dropped 18 percent, poly-unsaturated fatty acids
increased 82 percent, and omega-3 levels rose 70 percent compared to feeding no
flaxseed.
Similar improvements were observed
in butter and cheese.
Still, saturated fat accounted for
more than half of the fatty acids in the dairy products while the increase in
polyunsaturated fats comprised no more than nearly nine percent of the total.
Researchers noted that the
refrigerated butter was softer and less adhesive thanks to the presence of fewer
saturated fatty acids. Also, the cows produced the same amount of milk while
eating flaxseed.
Although flaxseed costs more than traditional
cattle feeds, Bobe hopes that it still could be an affordable feed supplement
for cows because products enriched with omega-3 can sell for a premium at the
grocery store.
"Many consumers already show a
willingness to pay extra for value-added foods, like omega-3 enriched
milk," he said. Fortunately cows loved eating flax seeds like candy.
Tuesday, August 7, 2012
The Great Impostors
The Great Impostors
Well said, hard hitting, if health services can be commercialized why not ecosystems?
Well said, hard hitting, if health services can be commercialized why not ecosystems?
Subscribe to:
Posts (Atom)